<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="In-Data-Review" Owner="NLM">        <PMID Version="1">30376844</PMID>        <DateRevised>            <Year>2018</Year>            <Month>11</Month>            <Day>18</Day>        </DateRevised>        <Article PubModel="Electronic">            <Journal>                <ISSN IssnType="Electronic">1755-8794</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>11</Volume>                    <Issue>1</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                        <Day>30</Day>                    </PubDate>                </JournalIssue>                <Title>BMC medical genomics</Title>                <ISOAbbreviation>BMC Med Genomics</ISOAbbreviation>            </Journal>            <ArticleTitle>Nucleotide excision repair is a predictor of early relapse in pediatric acute lymphoblastic leukemia.</ArticleTitle>            <Pagination>                <MedlinePgn>95</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1186/s12920-018-0422-2</ELocationID>            <Abstract>                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Nucleotide Excision Repair (NER) is a major pathway of mammalian DNA repair that is associated with drug resistance and has not been well characterized in acute lymphoblastic leukemia (ALL). The objective of this study was to explore the role of NER in relapsed ALL patients. We hypothesized that increased expression of NER genes was associated with drug resistance and relapse in ALL.</AbstractText>                <AbstractText Label="METHODS" NlmCategory="METHODS">We performed secondary data analysis on two sets of pediatric ALL patients that all ultimately relapsed, and who had matched diagnosis-relapse gene expression microarray data (GSE28460 and GSE18497). GSE28460 included 49 precursor-B-ALL patients, and GSE18497 included 27 precursor-B-ALL and 14 T-ALL patients. Microarray data were processed using the Plier 16 algorithm and the 20 canonical NER genes were extracted. Comparisons were made between time of diagnosis and relapse, and between early and late relapsing subgroups. The Chi-square test was used to evaluate whether NER gene expression was altered at the level of the entire pathway and individual gene expression was compared using t-tests.</AbstractText>                <AbstractText Label="RESULTS" NlmCategory="RESULTS">We found that gene expression of the NER pathway was significantly increased upon relapse in patients that took 3 years or greater to relapse (late relapsers, P = .007), whereas no such change was evident in patients that relapsed in less than 3 years (early relapsers, P = .180). Moreover, at diagnosis, the NER gene expression of the early relapsing subpopulation was already significantly elevated over that of the late relapsing group (P &lt; .001). This pattern was validated by an 'NER score' established by averaging the relative expression of the 20 canonical NER genes. The NER score at diagnosis was found to be significantly associated with disease-free survival in precursor-B-ALL (P &lt; .001).</AbstractText>                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Patients are over two times more likely to undergo early relapse if they have a high NER score at diagnosis, hazard ratio 2.008, 95% CI (1.256-3.211). The NER score may provide a underlying mechanism for &quot;time to remission&quot;, a known prognostic factor in ALL, and a rationale for differential treatment.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Ibrahim</LastName>                    <ForeName>Omar M</ForeName>                    <Initials>OM</Initials>                    <Identifier Source="ORCID">http://orcid.org/0000-0001-8976-6245</Identifier>                    <AffiliationInfo>                        <Affiliation>Department of Pharmaceutical Sciences, College of Pharmacy, 3200 S University Drive, Fort Lauderdale, FL, 33328, USA. oi23@nova.edu.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>AutoNation Institute for Breast and Solid Tumor Cancer Research, 3301 College Avenue, Fort Lauderdale, FL, 33314, USA. oi23@nova.edu.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>As Sobeai</LastName>                    <ForeName>Homood M</ForeName>                    <Initials>HM</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Pharmaceutical Sciences, College of Pharmacy, 3200 S University Drive, Fort Lauderdale, FL, 33328, USA.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>AutoNation Institute for Breast and Solid Tumor Cancer Research, 3301 College Avenue, Fort Lauderdale, FL, 33314, USA.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, P.O. Box 2475, Riyadh, 11451, Saudi Arabia.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Grant</LastName>                    <ForeName>Stephen G</ForeName>                    <Initials>SG</Initials>                    <AffiliationInfo>                        <Affiliation>AutoNation Institute for Breast and Solid Tumor Cancer Research, 3301 College Avenue, Fort Lauderdale, FL, 33314, USA.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Public Health, Dr. Kiran C. Patel College of Osteopathic Medicine, Nova Southeastern University, 3200 S University Drive, Fort Lauderdale, FL, 33328, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Latimer</LastName>                    <ForeName>Jean J</ForeName>                    <Initials>JJ</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Pharmaceutical Sciences, College of Pharmacy, 3200 S University Drive, Fort Lauderdale, FL, 33328, USA.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>AutoNation Institute for Breast and Solid Tumor Cancer Research, 3301 College Avenue, Fort Lauderdale, FL, 33314, USA.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>10</Month>                <Day>30</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>England</Country>            <MedlineTA>BMC Med Genomics</MedlineTA>            <NlmUniqueID>101319628</NlmUniqueID>            <ISSNLinking>1755-8794</ISSNLinking>        </MedlineJournalInfo>        <CommentsCorrectionsList>            <CommentsCorrections RefType="Cites">                <RefSource>Genes Chromosomes Cancer. 2004 Feb;39(2):161-6</RefSource>                <PMID Version="1">14695997</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Photochem Photobiol. 2015 Mar-Apr;91(2):493-500</RefSource>                <PMID Version="1">25393451</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Cancer Res. 2008 Mar 1;14(5):1291-5</RefSource>                <PMID Version="1">18316546</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Blood. 2011 Nov 10;118(19):5218-26</RefSource>                <PMID Version="1">21921043</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Srp Arh Celok Lek. 2008 Mar-Apr;136(3-4):187-92</RefSource>                <PMID Version="1">18720757</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Lancet Oncol. 2001 Aug;2(8):483-90</RefSource>                <PMID Version="1">11905724</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Immunol Res. 2012 Dec;54(1-3):233-46</RefSource>                <PMID Version="1">22569912</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Control. 2003 Jul-Aug;10(4):297-305</RefSource>                <PMID Version="1">12915808</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Leukemia. 2010 Mar;24(3):491-9</RefSource>                <PMID Version="1">20072147</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2001 Jul 1;19(13):3163-72</RefSource>                <PMID Version="1">11432882</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2007 Dec 20;25(36):5800-7</RefSource>                <PMID Version="1">18089878</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>CA Cancer J Clin. 2014 Mar-Apr;64(2):83-103</RefSource>                <PMID Version="1">24488779</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncotarget. 2016 May 24;7(21):30440-52</RefSource>                <PMID Version="1">27119507</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Pediatr Blood Cancer. 2006 May 1;46(5):570-8</RefSource>                <PMID Version="1">16365862</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Br J Haematol. 2016 Mar;172(5):655-66</RefSource>                <PMID Version="1">26568036</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer. 1998 Apr 1;82(7):1387-95</RefSource>                <PMID Version="1">9529033</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Pediatr Blood Cancer. 2011 Aug;57(2):210-6</RefSource>                <PMID Version="1">21337680</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Inform. 2008;6:423-31</RefSource>                <PMID Version="1">19259420</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Future Oncol. 2014 May;10(7):1215-37</RefSource>                <PMID Version="1">24947262</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Proc Natl Acad Sci U S A. 2010 Dec 14;107(50):21725-30</RefSource>                <PMID Version="1">21118987</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Blood. 2011 Mar 17;117(11):3010-5</RefSource>                <PMID Version="1">21193696</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Blood. 2009 Jan 1;113(1):117-26</RefSource>                <PMID Version="1">18941120</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Hum Genet. 2009 Oct;126(4):511-20</RefSource>                <PMID Version="1">19484265</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30</RefSource>                <PMID Version="1">26742998</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Genes Chromosomes Cancer. 2000 Nov;29(3):219-28</RefSource>                <PMID Version="1">10992297</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer. 1995 Dec 15;76(12):2393-417</RefSource>                <PMID Version="1">8625065</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Hematology Am Soc Hematol Educ Program. 2012;2012:129-36</RefSource>                <PMID Version="1">23233571</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Blood. 2014 Apr 10;123(15):2355-66</RefSource>                <PMID Version="1">24505083</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Pediatr Clin North Am. 2015 Feb;62(1):61-73</RefSource>                <PMID Version="1">25435112</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cell. 2002 Jan 25;108(2):153-64</RefSource>                <PMID Version="1">11832206</PMID>            </CommentsCorrections>        </CommentsCorrectionsList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Acute lymphoblastic leukemia</Keyword>            <Keyword MajorTopicYN="N">Childhood ALL</Keyword>            <Keyword MajorTopicYN="N">Early relapse</Keyword>            <Keyword MajorTopicYN="N">Late relapse</Keyword>            <Keyword MajorTopicYN="N">Nucleotide excision repair gene</Keyword>            <Keyword MajorTopicYN="N">Precursor-B-ALL</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>03</Month>                <Day>19</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>10</Month>                <Day>15</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>11</Month>                <Day>1</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>11</Month>                <Day>1</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>11</Month>                <Day>1</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>epublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30376844</ArticleId>            <ArticleId IdType="doi">10.1186/s12920-018-0422-2</ArticleId>            <ArticleId IdType="pii">10.1186/s12920-018-0422-2</ArticleId>            <ArticleId IdType="pmc">PMC6208034</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>